Petrelintide: Research & Studies

Research Overview#

Petrelintide is in early clinical development with Phase 1b data supporting proof of concept. The 8.6% weight loss at 4.8 mg over 16 weeks demonstrated meaningful efficacy for an amylin-only agent. The ZUPREME Phase 2b program will provide dose-ranging and combination data critical for advancing to Phase 3.

Phase 1b Results#

The Phase 1b study showed dose-dependent weight loss with petrelintide, achieving 8.6% body weight reduction at the highest evaluated dose of 4.8 mg. The drug was well tolerated with no dose-limiting toxicities, supporting further development.

Amylin as a Weight Loss Target#

Amylin analogs represent a distinct mechanism from GLP-1 agonists. Preclinical and clinical data suggest that amylin restores leptin sensitivity, amplifying the satiety signal. This has generated interest in amylin/GLP-1 combination approaches, as evidenced by the cagrilintide + semaglutide (CagriSema) program and now petrelintide + GLP-1 combinations.

Evidence Quality#

Research Evidence Context#

Petrelintide belongs to the Metabolic category of research peptides. The research evidence for Petrelintide spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Petrelintide:

Phase 1b Study of Petrelintide in Adults with Overweight or Obesity#

Authors: Zealand Pharma investigators (2024) — Conference presentation (Zealand Pharma)

Phase 1b dose-escalation study evaluating petrelintide once-weekly subcutaneous injection in adults with overweight or obesity. The highest dose of 4.8 mg achieved 8.6% body weight loss over 16 doses.

Key Findings:

• 8.6% body weight loss at 4.8 mg over 16 once-weekly doses
• Well tolerated with no dose-limiting toxicities
• Dose-dependent weight loss observed across dose levels
• Supports once-weekly dosing feasibility

Limitations: Phase 1b with small sample size; short treatment duration; press release data only; no active comparator

ZUPREME-1 Phase 2b Monotherapy Trial#

Authors: Roche/Zealand investigators (2025) — Ongoing trial

Phase 2b dose-ranging study of petrelintide monotherapy in adults with obesity. Currently enrolling under Roche sponsorship.

Key Findings:

• Trial ongoing; no results yet available

Limitations: Ongoing trial; no interim data disclosed

ZUPREME-2 Phase 2b Combination Trial#

Authors: Roche/Zealand investigators (2025) — Ongoing trial

Phase 2b study of petrelintide in combination with a GLP-1 receptor agonist for enhanced weight loss. Tests the hypothesis that complementary amylin and GLP-1 mechanisms produce additive or synergistic weight loss.

Key Findings:

• Trial ongoing; no results yet available

Limitations: Ongoing trial; no interim data disclosed

Evidence Quality Assessment#

The overall evidence level for Petrelintide is classified as low. Available research includes limited clinical data, typically from small or early-phase studies. More rigorous clinical trials are needed to draw definitive conclusions.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Petrelintide have been identified:

• No Phase 2b efficacy data yet available
• Optimal dose for monotherapy not established
• Combination efficacy with GLP-1 agonists unproven in clinical trials
• Long-term safety data not available
• No head-to-head comparison with cagrilintide or other amylin analogs
• Leptin sensitization mechanism not confirmed in human studies

Addressing these research gaps will be important for establishing a more complete understanding of Petrelintide's therapeutic potential and safety profile.

Related Reading#

• Petrelintide overview and research guide
• Petrelintide dosing protocols
• Petrelintide molecular structure